In conclusion, the data suggest that FGB and C4A can be considered as plasma potential biomarkers so that diagnosis of CRC patients and understanding the underlying procedures in tumorigenesis to be accelerated; although, it demands more extensive and cohorts studies. The gene discussed is FGB; the disease is colorectal carcinoma.